(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 March 2019 (28.03.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/060726 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *C12N 15/861* (2006.01)
A61K 31/713 (2006.01)

(21) International Application Number:
PCT/US2018/052221

(22) International Filing Date:
21 September 2018 (21.09.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/561,843 22 September 2017 (22.09.2017) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 50 Binney Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **O'RIORDAN, Catherine R.**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **PALERMO, Adam**; 280 River St., #3, Cambridge, Massachusetts 02139 (US). **RICHARDS, Brenda**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **STANEK, Lisa M.**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US).

(74) Agent: **DONAHUE, Brian**; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: VARIANT RNAI

(57) Abstract: Provided herein are RNAi molecules for treating Huntington' s disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.

WO 2019/060726 A1